EXAS Exact Sciences
- 53.490
- -0.030-0.06%
Exact Sciences News
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $100
TD Cowen analyst Daniel Brennan maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 52.9% and a
Court Dismisses Exact Sciences' '781 Patent Infringement Claim Against Geneoscopy
Geneoscopy Continues Path Toward Commercialization of ColoSense, Bringing New Innovations in Gastrointestinal Health to Patients in Need Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests
Exact Sciences Earns 2024 Great Place To Work Certification
Award marks sixth consecutive year company has received prestigious distinction Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been
Analysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)
Guardant Health Slips as FDA Comments on Cancer Screening Test
Exact Sciences Patent Infringement Case Against Geneoscopy to Proceed
Most Attractive Short-term Overwriting Stocks for June Expiration - Goldman
Goldman Sachs analysts identified short-term overwriting opportunities in large-cap, high implied volatility stocks that do not have earnings events.
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Exact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net Loss
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients
LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recomme
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Optimistic Outlook for Exact Sciences: Overcoming Challenges With Growth Initiatives and New Product Potential
Top Gap Ups and Downs on Thursday: TTE, ABNB, EQIX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Exact Sciences Price Target Cut to $85.00/Share From $90.00 by Canaccord Genuity
Exact Sciences Price Target Cut to $85.00/Share From $90.00 by Canaccord Genuity
Exact Sciences Is Maintained at Buy by Citigroup
Exact Sciences Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $80
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 46.33% Citigroup $100 → $80 Maintains Buy 04/03/2024 82.92% Citigroup → $100 Maintains Buy 02/2
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve i
Analysis
Price Target
No Data
